Table 3.
Univariate/Multivariate analysis of prognostic factors for time to recurrence.
| Variable | Univariate Analysis | P-Value | Multivariate Analysis | P-Value |
|---|---|---|---|---|
| Age (reference ≤ 65 years) | 2.02 (1.27–3.21) | 0.002 | 1.59 (0.73–2.34) | 0.21 |
| Gender (reference female) | 1.63 (0.89–3.01) | 0.07 | ||
| Blood hypertension (reference no) | 1.28 (0.82–1.74) | 0.79 | ||
| BMI (reference ≤ 25) | 1.34 (0.89–1.78) | 0.21 | ||
| Mellitus diabetes (reference no) | 1.46 (0.91–2.04) | 0.16 | ||
| Etiology (reference HBV) | HCV: 0.92 (0.78–1.35) Other: 1.24 (0.87–3.89) |
0.39 | ||
| Child-Pugh (reference A) | 1.05 (0.57–1.92) | 0.87 | ||
| Portal hypertension (reference no) | 0.73 (0.47–1.14) | 0.16 | ||
| AFP (reference ≤ 20 IU/mL) | 1.10 (0.73–1.66) | 0.62 | ||
| MELD (reference ≤ 7) | 0.73 (0.43–1.24) | 0.25 | ||
| Max diameter (reference ≤ 30 mm) | 0.90 (0.54–1.51) | 0.71 | ||
| BCLC (reference 0) | 1.11 (0.59–2.09) | 0.72 | ||
| CLIP (reference 0) | 1: 1.51 (0.8–3.3) 2: 3.9 (0.91–7.2) |
0.15 | ||
| Number of nodules (reference 1) | 2.45 (1.32–3.04) | 0.02 | 1.45 (1.02–3.01) | 0.04 |
| Anti-angiotensin therapy (reference none) |
ACE I: 0.71 (0.46–1.12) Sartans: 0.49 (0.28–0.84) |
0.001 0.44 * 0.03 * |
0.78 (0.49–1.22) 0.47 (0.27–0.82) |
0.008 0.31 * 0.009 * |
Reported as Hazard Ratio (95% CI). Significancies were reported in bold. Abbreviations: CI 95%, confidence interval 95%; BMI, Body Mass Index; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; MELD, Model for End-Stage Liver Disease; BCLC, Barcelona Cancer of the Liver Clinic; CLIP, Cancer of the Liver Italian Program. * Correction by means of Bonferroni method.